PHAS PhaseBio Pharmaceuticals Inc.

10.75
-0.47  -4%
Previous Close 11.22
Open 11.23
Price To Book 6.98
Market Cap 307,739,713
Shares 28,626,950
Volume 102,374
Short Ratio
Av. Daily Volume 197,687

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 2020.
PB1046
Pulmonary arterial hypertension (PAH)
Phase 2a initial data released June 17, 2019.
PB2452
Reversal agent for ticagrelor

Latest News

  1. PhaseBio Added to Russell 2000® and 3000® Indexes
  2. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating PhaseBio Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  3. The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale
  4. PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects
  5. PhaseBio Reports First Quarter 2019 Financial Results and Recent Corporate Progress
  6. PhaseBio To Report First Quarter 2019 Financial Results and Recent Corporate Progress on May 9, 2019
  7. 2 Ultra-High Growth Stocks to Buy Now
  8. PhaseBio completes $49.5M stock sale
  9. PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  10. Billionaires Are Betting This Could Be One Of The Biggest Industries In History
  11. PhaseBio plans $43M stock sale
  12. PhaseBio Announces Pricing of Public Offering of Common Stock
  13. The Daily Biotech Pulse: Amgen's Bone-Building Osteoporosis Drug Clears FDA Muster, PhaseBio Offering
  14. PhaseBio Announces Proposed Public Offering of Common Stock
  15. Why PhaseBio's stock rose 16 percent Tuesday
  16. Here's Why PhaseBio Pharmaceuticals Rose as Much as 32.5% Today
  17. PhaseBio Stock Up on Breakthrough Therapy Status for PB2452
  18. The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing
  19. Dow Jones Futures: Zogenix Leads 3 Big Movers On FDA News